InvestorsHub Logo
Followers 59
Posts 687
Boards Moderated 0
Alias Born 01/22/2023

Re: iclight post# 688055

Tuesday, 04/30/2024 1:45:26 PM

Tuesday, April 30, 2024 1:45:26 PM

Post# of 709948
So your saying the 60+ JAMA Oncology peer review Authors were wrong when they came to the conclusion:

Conclusions
This phase 3, nonrandomized, externally controlled trial found that the addition of DCVax-L to SOC was associated with a clinicallymeaningful and statistically significant extension of overall survival in both nGBM and rGBM. Treatment with DCVax-L also had an excellent safety profile and noteworthy tails of longterm survival curves.



https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News